Position Paper on HPV Immunization

Despite these recommendations, less than 25% of AYA cancer survivors report initiating the

HPV vaccine (Klosky et al., 2017). Cancer survivors are less likely than peers to report a

healthcare provider recommendation for the HPV vaccine, yet provider recommendation is the

strongest predictor for HPV vaccine initiation among cancer survivors (Klosky et al., 2017).

Pediatric hematology/oncology nurses should address this gap by incorporating HPV vaccine

recommendation into hematology/oncology nursing practice. Adolescent and young adult cancer

survivors and patients with hematologic disorders have the right to receive education about

cancer prevention, including the HPV vaccine, and pediatric hematology/oncology nurses have

the responsibility to promote vaccination among cancer survivors and patients with hematologic


 APHON supports equity of access to HPV immunization.

Economic Considerations

HPV vaccination has been evaluated for cost effectiveness within the United States and

internationally among the general population. The currently recommended nonavalent vaccine is

considered cost effective, particularly when administered during early adolescence (Brisson et

al., 2013; Chesson, Markowitz, Hariri, Ekwueme, & Saraiya, 2016; Simms et al., 2016; World

Health Organization, 2017). In countries with universal health care or school-based

immunization programs, there usually is no cost to the patient. In the United States, the cost of

the HPV vaccine may be covered by private insurance policies, governmental programs, or

pharmaceutical company patient assistance programs (Centers for Disease Control and

Prevention, 2016).

Powered by